|
|
Last Modified: 7/11/2007  First Published: 2/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Supportive care, Treatment
|
|
|
|
Completed
|
|
|
|
12 to 50
|
|
|
|
Other
|
|
|
|
CHIMERIC-HM01 WSU-10-02-99-M01-FB, NCT00004255
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 79
|
|
|
|
|
|
|
|
EORTC-06942
|
|
|
|
|
|
|
|
Last Modified: 8/12/2008  First Published: 8/1/1996 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Under 22
|
|
|
|
NCI
|
|
|
|
COG-2961 CCG-2961, NCT00002798
|
|
|
|
|
|
|
|
Last Modified: 5/11/2007  First Published: 3/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
ECOG-2997 CALGB-10103, SWOG-E2997, NCT00003764, E2997
|
|
|
|
|
|
|
|
Last Modified: 1/4/2008  First Published: 2/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
LRF-CLL4 LRG-MRC-LEUK-CLL4, EU-99030, MRC-LEUK-CLL4, NCT00004218, EUDRACT-58585610, ISRCTN58585610
|
|
|
|
|
|
|
|
Last Modified: 7/11/2007  First Published: 6/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Any age
|
|
|
|
Other
|
|
|
|
MRC-LEUK-AML-HR EU-20008, NCT00005863
|
|
|
|
|
|
|
|
Last Modified: 1/4/2008  First Published: 9/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 70
|
|
|
|
Other
|
|
|
|
BNLI-MCD/FMD EU-20035, NCT00006250
|
|
|
|
|
|
|
|
Last Modified: 6/10/2004  First Published: 6/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
EORTC-06992-CLL-3 NCT00017108
|
|
|
|
|
|
|
|
Last Modified: 2/17/2007  First Published: 9/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Over 18
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
GENTA-GL303 UCLA-0104008, NCT00024440
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CLB-9011 CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1
|
|
|
|